Loading
Rani Therapeutics Holdings, Inc. Stock: price and insider trades · United States
2 insiders bought €44k of shares over the last 90 days, the latest filed 23 Jul 2026.
Rani Therapeutics Holdings, Inc.: what insiders have been doing
Rani Therapeutics Holdings, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 4 insiders have disclosed 15 filings since 18 October 2025.
Both sides are active: 3 purchases worth €1.1M and 3 sales worth €4.0M, from 2 insiders and 3 insiders respectively. Sales outweigh purchases by €2.9M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 senior executive and 1 chief executive among the declarants. Biggest ticket of the year: €4.0M, sold by South Cone Investments Limited Partnership and made public on 22 October 2025.
Compared with its exchange (5,810 companies, median 19 filings), a count of 15 filings is below the norm. Our records for Rani Therapeutics Holdings, Inc. go back to 2021, with 54 purchases and 7 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 1.6 m USD of revenue and -29.7 m USD of net income.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (23 July 2026) now reads 86 days. Typically, a trade is published a median of 24 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
95
Thresholds
n/a
Buy Volume
€14M
54 ops. · all time
Sell Volume
€23M
7 ops. · all time
Who traded when
BuySaleTalat Imran2 buys1 sale
Mir A. Imran2 buys
Alireza Javadi1 sale
Kate McKinley1 buy
South Cone Investments Limited Partnership1 sale
Since the insiders bought
- -20.1%Entry US$0.85 · Close 15 Oct 2026 US$0.68
- -24.2%Entry US$0.90 · Close 15 Oct 2026 US$0.68
- +4.6%Entry US$11.83 · Close at T+365 US$12.38
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Rani Therapeutics Holdings, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$7.20.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.73
Analyst consensus
5 analystsStrong buy
US$5.00Target US$7.20(+882%)US$11.00
Income statement
RevenueUS$1.6M
EBITDA-US$37.2M-2276% margin
Net income-US$29.7M-1817.1% margin
Valuation
PER (forward)-3.9x
P/Book2.1x
Beta0.71
Balance sheet & cash
Market capUS$103M
Total debtUS$4.3M
Free Cash Flow-US$18.8M
Debt / Equity7%
Profitability & ownership
ROE-172.1%
ROA-53.0%
% insiders4.9%
% institutions46.8%
Last declaration on 29 September 2026
Declarations95 total
7,928 shares@ US$0.75920.0055% mcap2.7% of flowClass A Common StockSEC:0001193125-26-407684:0
309 shares@ US$0.75920.0002% mcap30.8% of flowClass A Common StockSEC:0001193125-26-407648:0
36,000 shares@ US$0.690.023% mcap1.2% of flowClass A Common StockSEC:0001031686-26-000006:0
Canonical exit: 19 Oct 2026 (T+90)
8,014 shares@ US$1.415.2% of flowClass A Common StockSEC:0001869579-26-000006:0
9,076 shares@ US$0.552.1% of flowClass A Common StockSEC:0001869579-26-000006:1
309 shares@ US$0.740.0002% mcap43.5% of flowClass A Common StockSEC:0002123843-26-000008:1
7,927 shares@ US$0.740.0062% mcap2.7% of flowClass A Common StockSEC:0001869579-26-000006:6
9,077 shares@ US$0.481.9% of flowClass A Common StockSEC:0001869579-26-000006:2
7,906 shares@ US$1.404.9% of flowClass A Common StockSEC:0001869579-26-000006:3
8,916 shares@ US$1.134.5% of flowClass A Common StockSEC:0001869579-26-000006:4
9,099 shares@ US$0.813.3% of flowClass A Common StockSEC:0001869579-26-000006:5
35,000 shares@ US$0.71980.023% mcap11.4% of flowClass A Common StockSEC:0001869579-26-000007:0
Canonical exit: 15 Oct 2026 (T+90)
386 shares@ US$0.7856.5% of flowClass A Common StockSEC:0002123843-26-000008:0
2,083,334 shares@ US$0.60559.0% of flowClass A Common StockSEC:0001031686-25-000004:0
Canonical exit: 21 Jan 2026 (T+90)
1,923,000 shares@ US$2.411517.6% of flowClass A Common StockSEC:0001104659-25-101613:0
17,960 shares@ US$1.67100.0% of flowClass A Common StockSEC:0000950170-24-136787:0
Canonical exit: 13 Mar 2025 (T+90)
10,296 shares@ US$1.949.8% of flowClass A Common StockSEC:0000950170-24-134828:0
Canonical exit: 9 Mar 2025 (T+90)
3,305,622 shares@ US$2.552134.2% of flowClass A Common StockSEC:0001104659-24-109543:0
5,265,165 shares@ US$2.0142.8% of flowClass A Common StockSEC:0001104659-23-124719:0
Canonical exit: 22 Feb 2024 (T+90)
5,265,165 shares@ US$2.0197.4% of flowClass A Common StockSEC:0001104659-23-124723:0
10,000 shares@ US$2.2710.9% of flowClass A Common StockSEC:0000950170-23-068864:0
Canonical exit: 5 Mar 2024 (T+90)
5,000 shares@ US$2.576.1% of flowClass A Common StockSEC:0000950170-23-068442:0
Canonical exit: 3 Mar 2024 (T+90)
20,000 shares@ US$2.0519.3% of flowClass A Common StockSEC:0000950170-23-067149:0
Canonical exit: 27 Feb 2024 (T+90)
50,500 shares@ US$2.0296100.0% of flowClass A Common StockSEC:0000950170-23-065474:0
Canonical exit: 15 Feb 2024 (T+90)
500 shares@ US$1.98100.0% of flowClass A Common StockSEC:0000950170-23-064982:0
Canonical exit: 14 Feb 2024 (T+90)
25 of 95 declarations
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. is a U.S.-based biotechnology company listed on the Nasdaq market (United States) and focused on oral delivery of biologics and drugs that are traditionally administered by injection or infusion. The company’s core thesis is that many high-value therapies could be transformed into patient-friendly oral treatments through its proprietary RaniPill platform, an ingestible capsule designed to deploy a precise dose in the small intestine. In equity terms, this places Rani in the clinical-stage, platform-biotech category: it is not yet a mature commercial drug company, but rather a developer of enabling technology with optionality across multiple therapeutic areas. ([ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/?utm_source=openai))
Rani Therapeutics was built around a differentiated drug-delivery concept and an extensive intellectual-property portfolio. Its headquarters are in San Jose, California, anchoring the company in one of the most established biotechnology clusters in the United States. The firm’s development strategy is to prove that the RaniPill can reliably deliver complex biologics orally, potentially replacing subcutaneous injections and improving adherence, convenience, and patient experience. The company’s investor materials describe several preclinical and clinical studies supporting the platform’s safety, tolerability, and bioavailability profile. ([ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/?utm_source=openai))
Read moreShow less
Operationally, Rani’s business lines center on platform development, preclinical validation, clinical advancement, and strategic partnering. Rather than depending on a single asset, the company is trying to establish the RaniPill as a repeatable delivery technology for multiple molecules. Recent disclosures show a growing focus on metabolic disease and other biologics-heavy categories. In March 2026, Rani reported preclinical data showing successful oral delivery of semaglutide and preclinical bioequivalence data for RT-114, a bispecific GLP-1/GLP-2 dual agonist. It also initiated a Phase 1 study of RT-114 for obesity in collaboration with ProGen. ([nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results?utm_source=openai))
From a competitive standpoint, Rani operates in a demanding segment where success depends on clinical proof, manufacturability, regulatory execution, and the ability to attract pharmaceutical partners. Its main competitive edge is the potential to convert injectable biologics into oral medicines, a proposition that could be highly disruptive if replicated at scale. That said, the company remains exposed to the usual risks of clinical-stage biotech: execution risk, regulatory uncertainty, and the need for continued capital access. In November 2025, Rani announced a collaboration potentially worth up to $1.085 billion with Chugai Pharmaceutical and completed a $60.3 million oversubscribed private placement. The company also said its cash runway was expected to extend into 2028, a meaningful development for a precommercial biotech. ([nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-third-quarter-2025-financial-results-provides-corporate?utm_source=openai))
For international investors, Rani Therapeutics is best viewed as a high-risk, high-upside platform story within healthcare and pharmaceuticals. The key monitoring points are clinical readouts, partner momentum, and the company’s ability to translate its technology into a broader pipeline and ultimately commercial value. Its Nasdaq listing and U.S. headquarters are central reference points, but the investment case will ultimately depend on whether the RaniPill can become a scalable delivery standard for biologics. ([nasdaq.com](https://www.nasdaq.com/press-release/rani-therapeutics-reports-third-quarter-2025-financial-results-provides-corporate?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
